"2-Naphthylamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A naphthalene derivative with carcinogenic action.
Descriptor ID |
D015081
|
MeSH Number(s) |
D02.092.710 D02.455.426.559.847.638.850 D04.615.638.850
|
Concept/Terms |
2-Naphthylamine- 2-Naphthylamine
- 2 Naphthylamine
- beta-Naphthylamine
- beta Naphthylamine
- 2-Aminonaphthalene
- 2 Aminonaphthalene
|
Below are MeSH descriptors whose meaning is more general than "2-Naphthylamine".
Below are MeSH descriptors whose meaning is more specific than "2-Naphthylamine".
This graph shows the total number of publications written about "2-Naphthylamine" by people in this website by year, and whether "2-Naphthylamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2016 | 0 | 2 | 2 |
2017 | 0 | 12 | 12 |
2018 | 0 | 11 | 11 |
2019 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "2-Naphthylamine" by people in Profiles.
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.
-
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. Eur J Gastroenterol Hepatol. 2019 04; 31(4):534-539.
-
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat. 2019 06; 26(6):685-696.
-
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018 12; 62:94-103.
-
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Ann Hepatol. 2018 Oct 16; 17(6):959-968.
-
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection. 2018 Oct; 46(5):607-615.
-
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018 07; 48(1):35-43.
-
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. Liver Int. 2018 08; 38(8):1395-1401.
-
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era. Antivir Ther. 2018; 23(7):605-609.